Compare Dropbox Inc (DBX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Recursion Pharmaceuticals Inc — how do they compare? Dropbox Inc trades at $29.53 (market cap $6.99B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.78B). The key difference: Dropbox Inc is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| DBX | RXRX | |
|---|---|---|
Market Cap | $6.99B | $1.78B |
Sector | Technology | Health |
52-Week High | $32.17 | $6.79 |
52-Week Low | $22.06 | $2.84 |
Enterprise Value | $9.71B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $29.58, up 1.34% on the day, near the analyst consensus price target of $30. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate potential overbought conditions. Fundamentally, the company maintains robust profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent news highlights a new $900 million stock repurchase program and a CEO transition plan announced in May 2026.
The outlook is balanced with solid fundamentals and shareholder returns offset by high debt levels and mixed analyst sentiment. Investment appeal lies in consistent earnings beats and capital return initiatives, but risks include elevated leverage and competitive pressures in cloud storage. The stock presents a moderate opportunity with cautious optimism warranted given its valuation near target prices.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
